PRECISE-DAPT Score

Calculate the PRECISE-DAPT score (0–100) for bleeding risk on dual antiplatelet therapy after PCI. Stratify non-high, moderate, and high risk to guide individualized DAPT duration.

PRECISE-DAPT Score Calculator

Enter baseline clinical and laboratory values at the time of PCI or discharge to estimate out-of-hospital bleeding risk on dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor). Use creatinine clearance, not serum creatinine.

Clinical variables

Age (years)Hemoglobin

Example: 140 g/L = 14.0 g/dLWhite blood cell count (×10⁹/L)Equivalent to K/µL or 10³/µLCreatinine clearance (mL/min)

Prior spontaneous bleeding requiring medical attention

Disclaimer: The PRECISE-DAPT score is an educational clinical decision-support tool derived primarily from patients on aspirin plus clopidogrel without chronic oral anticoagulation. It does not replace comprehensive cardiovascular assessment, ischemic risk stratification (e.g., DAPT score), or shared decision-making. Avoid rigid cutoffs; interpret results in the full clinical context.

PRECISE-DAPT Score: formula, variables, and clinical context

Overview

The PRECISE-DAPT score (Predicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy) estimates out-of-hospital TIMI major or minor bleeding risk in patients treated with dual antiplatelet therapy (DAPT) after percutaneous coronary intervention. It was derived from a pooled analysis of 14,963 patients across eight randomized trials and externally validated in PLATO and BernPCI cohorts (Costa et al., Lancet 2017).

Scoring method

The score uses a bedside nomogram. For each of the five variables, read the corresponding points from the nomogram axis (values outside published ranges are truncated at the limits), then sum all points. The total score ranges from 0 to 100.

Nomogram variables and axis limits

Variable	Input range (truncated outside limits)	Points range
Age	50–90 years	0–19
Hemoglobin	10–12 g/dL (100–120 g/L)	15–0
Creatinine clearance	0–100 mL/min	25–0
White blood cell count	5–20 ×10⁹/L	0–15
Prior spontaneous bleeding	Yes / No	26 / 0

Lower hemoglobin and creatinine clearance, higher age and WBC, and prior bleeding each contribute more points. Hemoglobin above 12 g/dL and creatinine clearance above 100 mL/min contribute 0 points on those axes.

Risk stratification

Score	Category	DAPT duration consideration
≤17	Non-high bleeding risk	Standard or extended DAPT may be reasonable if ischemic risk is high
18–24	Moderate bleeding risk	Individualize; balance bleeding and ischemic risk
≥25	High bleeding risk (HBR)	Consider short DAPT (3–6 months) when ischemic risk is low or bleeding is a concern

When to use

At the time of PCI or hospital discharge in patients receiving aspirin plus a P2Y12 inhibitor (primarily studied with clopidogrel).
To inform shared decision-making on DAPT duration (short 3–6 months vs. standard or extended therapy).
Not validated in patients on triple therapy (OAC plus DAPT), post-CABG, or chronic oral anticoagulation.

Key references

Costa F, van Klaveren D, James S, et al. Derivation and validation of the PRECISE-DAPT score. Lancet. 2017;389(10073):1025-1034.
Valgimigli M, et al. 2017 ESC Focused Update on DAPT in Coronary Artery Disease. Eur Heart J. 2018;39(3):213-260.
Munafò AR, et al. External validity of the PRECISE-DAPT score: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2023;9(8):709-721.

Practice caveats

Combine with an ischemic risk tool (e.g., DAPT score) for balanced decision-making.
Discrimination is moderate (C-statistic approximately 0.66–0.73 across cohorts); use as decision support, not a rigid rule.
A simplified 4-item version omitting WBC retains similar performance when WBC is unavailable (Costa et al., Am Heart J 2020).
Reassess if renal function, hemoglobin, or clinical status changes during follow-up.

What is the PRECISE-DAPT score?

The PRECISE-DAPT score (Predicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual AntiPlatelet Therapy) is a validated nomogram that estimates out-of-hospital bleeding risk in patients treated with dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). It was derived from a pooled individual-patient analysis of randomized trial datasets and published by Costa and colleagues in The Lancet (2017).

Unlike scores that predict ischemic events or stent thrombosis, PRECISE-DAPT is designed specifically to inform how long to continue DAPT by identifying patients in whom prolonged therapy (for example, beyond 12 months) is more likely to cause bleeding harm than ischemic benefit, and patients in whom longer therapy remains favorable when clinically indicated.

The total score ranges from 0 to 100, with higher values indicating greater predicted bleeding risk. It is a bleeding risk stratification tool for shared decision-making, not a substitute for comprehensive cardiovascular assessment, ischemic risk scores (such as the DAPT score), or institutional protocols.

Clinical context: DAPT after PCI

After coronary stent implantation, guidelines recommend DAPT with aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) for a minimum duration that depends on presentation (stable angina versus acute coronary syndrome), stent type, and bleeding versus ischemic risk. Standard courses often span 6 to 12 months; selected patients with high ischemic risk and low bleeding risk may receive extended DAPT beyond 12 months, while others with high bleeding risk may receive shortened DAPT (3 to 6 months) followed by single antiplatelet therapy (SAPT).

Balancing these risks is challenging because major bleeding on DAPT carries substantial morbidity and mortality, yet premature discontinuation increases risk of stent thrombosis and recurrent ischemic events. PRECISE-DAPT helps quantify bleeding risk using routinely available baseline variables at the time of PCI or hospital discharge, when duration decisions are often made.

The derivation cohort consisted primarily of patients on aspirin plus clopidogrel without chronic oral anticoagulation. Scores should be applied cautiously in patients on potent P2Y12 inhibitors, triple therapy, or direct oral anticoagulants, where absolute bleeding rates differ from the original trials.

Outcome predicted

PRECISE-DAPT was developed to predict out-of-hospital TIMI major or minor bleeding during follow-up on DAPT. In the pooled analysis, a score ≥ 25 identified patients with significantly higher bleeding when DAPT was prolonged, whereas scores ≤ 17 identified patients who did not show excess bleeding with longer therapy and who could derive ischemic benefit from extended DAPT when clinically appropriate. Intermediate scores require careful weighing of competing risks.

Patient population and when to apply the score

Apply PRECISE-DAPT in adults who have undergone PCI and are planned for or already receiving DAPT, typically at the time of discharge or when reconsidering duration at follow-up. Enter baseline clinical and laboratory values from that time point; the score is not intended for serial recalculation at every visit unless clinical status has materially changed (for example, new bleeding, renal decline, or anemia).

Use creatinine clearance (CrCl) in mL/min, not serum creatinine alone. Cockcroft-Gault or a validated estimated glomerular filtration rate conversion to clearance is commonly used in practice.

PRECISE-DAPT addresses bleeding risk only. Always pair it with ischemic risk assessment (clinical presentation, stent type, completeness of revascularization, diabetes, prior MI, DAPT score where applicable, and patient preferences) before shortening or extending therapy.

Scoring variables and nomogram points

Five variables contribute to the score through linear nomogram axes (values outside published axis limits are truncated to the minimum or maximum of each axis). Component points are summed and the total is rounded to the nearest integer.

Variable	Input	Nomogram axis	Points at axis minimum	Points at axis maximum
Age	Years	50 to 90 years	0 (at 50 years)	19 (at 90 years)
Hemoglobin	g/L or g/dL	100 to 120 g/L (10.0 to 12.0 g/dL)	15 (at 100 g/L)	0 (at 120 g/L)
Creatinine clearance	mL/min	0 to 100 mL/min	25 (at 0 mL/min)	0 (at 100 mL/min)
White blood cell count	×10⁹/L	5 to 20 ×10⁹/L	0 (at 5)	15 (at 20)
Prior spontaneous bleeding	Yes / No	Binary	0 (No)	26 (Yes)

Total PRECISE-DAPT score = sum of all five components (range 0–100).

Variable definitions and rationale

Age (50–90 years, up to 19 points): Older age is a consistent predictor of bleeding on antiplatelet therapy. Patients younger than 50 receive 0 age points; patients older than 90 receive the maximum 19 points.
Hemoglobin (100–120 g/L, up to 15 points): Lower hemoglobin reflects anemia and associates with bleeding. Points decrease linearly as hemoglobin rises from 100 g/L (15 points) to 120 g/L (0 points). Values below 100 g/L receive the maximum 15 points; values above 120 g/L receive 0. Enter hemoglobin in g/L or g/dL (multiply g/dL by 10 to obtain g/L; for example, 14.0 g/dL = 140 g/L).
Creatinine clearance (0–100 mL/min, up to 25 points): Renal impairment increases bleeding risk and is weighted heavily in the nomogram. CrCl of 0 mL/min receives 25 points; CrCl of 100 mL/min or higher receives 0 points.
White blood cell count (5–20 ×10⁹/L, up to 15 points): Higher WBC counts contribute additional points from 0 at 5 ×10⁹/L to 15 at 20 ×10⁹/L. This unit is equivalent to K/µL or 10³/µL.
Prior spontaneous bleeding requiring medical attention (0 or 26 points): A history of spontaneous bleeding (not procedure-related) that required medical attention adds a fixed 26 points, the largest single component. This captures prior bleeding diathesis not fully reflected in laboratory values alone.

Worked example

A 72-year-old patient with hemoglobin 115 g/L (11.5 g/dL), creatinine clearance 45 mL/min, WBC 8 ×10⁹/L, and no prior spontaneous bleeding might receive approximately: age 11 points, hemoglobin 3.75 points, CrCl 13.75 points, WBC 3 points, bleeding 0 points, for a total near 32 (high bleeding risk category). Exact component decimals depend on linear interpolation; the calculator rounds the final score.

Risk stratification and DAPT duration implications

PRECISE-DAPT divides patients into three management-oriented categories. These thresholds match the CalcMD implementation and the original publication framework.

PRECISE-DAPT score	Risk category	Bleeding risk framing	DAPT duration guidance
≤ 17	Non-high bleeding risk	Lower predicted out-of-hospital bleeding on DAPT	Standard or extended DAPT may be reasonable, particularly when ischemic risk is high (for example, prior MI, complex PCI, diabetes). Individualize based on stent type, presentation, and guidelines.
18–24	Moderate bleeding risk	Intermediate bleeding risk	Individualize DAPT duration. Weigh bleeding versus ischemic risk carefully; shared decision-making is especially important in elderly or borderline patients. Shorter DAPT may be considered if bleeding concerns predominate; standard duration if ischemic risk is elevated.
≥ 25	High bleeding risk (HBR)	High predicted bleeding; prolonged DAPT may cause net harm in pooled analyses when ischemic risk is low	Consider short DAPT (3–6 months) if ischemic risk is low or bleeding is a primary concern, then transition to single antiplatelet therapy. Reassess if renal function, hemoglobin, or clinical status changes.

Interaction with DAPT duration: how to use the score clinically

The central finding of the PRECISE-DAPT analysis is an interaction between bleeding risk score and DAPT duration:

Patients with scores ≥ 25 had higher bleeding with prolonged DAPT and may derive greater net benefit from shorter therapy when ischemic risk does not mandate extension.
Patients with scores ≤ 17 did not show excess bleeding with longer DAPT in pooled data and may experience ischemic benefit from standard or extended therapy when clinically indicated.
Patients with intermediate scores (18–24) fall in a gray zone where neither blanket shortening nor extension is supported without individualized assessment.

PRECISE-DAPT does not mandate a single duration for all patients in a category. It informs the bleeding side of the balance. A young patient with a large anterior STEMI, left main PCI, and diabetes may still warrant longer DAPT despite a moderate score if ischemic risk dominates and bleeding is manageable. Conversely, an elderly patient with anemia, renal impairment, and prior GI bleeding may warrant short DAPT even at a moderate score if ischemic risk is low.

Complementary tools: ischemic risk and high bleeding risk definitions

PRECISE-DAPT should be used alongside, not instead of, ischemic risk stratification:

The DAPT score (different acronym, different purpose) estimates ischemic benefit from continuing DAPT beyond 12 months using stent type, prior MI, PCI characteristics, diabetes, smoking, and congestive heart failure. A patient with a high DAPT score (ischemic benefit expected) and a high PRECISE-DAPT score (bleeding risk expected) exemplifies the classic tradeoff requiring shared decision-making.
Academic Research Consortium (ARC-HBR) criteria define high bleeding risk using a checklist of clinical features. PRECISE-DAPT provides a continuous 0–100 scale derived from trial bleeding outcomes rather than a binary checklist, though scores ≥ 25 align conceptually with high bleeding risk in many pathways.

Document both bleeding and ischemic assessments when discussing duration with patients.

Practical measurement tips

Hemoglobin: Use the value closest to PCI or discharge; acute blood loss or transfusion before measurement may misclassify risk.
Creatinine clearance: Calculate with Cockcroft-Gault or use institutional standard; do not substitute serum creatinine alone into the nomogram.
WBC: Acute infection or corticosteroids can elevate WBC transiently; consider whether the value reflects baseline status.
Prior bleeding: Include spontaneous bleeding that required medical attention (for example, gastrointestinal hemorrhage requiring transfusion or hospitalization). Exclude minor epistaxis or expected surgical bleeding unless it meets the clinical threshold used in trials.

Important limitations and practice caveats

Derivation population: Primarily aspirin plus clopidogrel without chronic oral anticoagulation; extrapolation to ticagrelor, prasugrel, or triple therapy requires caution.
Not an ischemic score: Low bleeding risk does not mean low ischemic risk; always assess thrombotic risk separately.
Not a mandate: Avoid rigid application of cutoffs without clinical context, patient values, and guideline recommendations.
Axis truncation: Extreme values are capped at nomogram limits (for example, age under 50 still contributes 0 age points).
Timing: Intended for baseline assessment at PCI or discharge; major changes in renal function, hemoglobin, or bleeding history warrant reassessment.
Out-of-hospital bleeding: The outcome is trial-defined TIMI major or minor bleeding; real-world bleeding definitions may differ slightly.
Does not replace multidisciplinary review: Complex cases (left main, bifurcation, prior stroke, atrial fibrillation) need specialist input beyond any single score.

Documentation and workflow tips

When using PRECISE-DAPT in practice, document each input (age, hemoglobin with units, CrCl, WBC, prior bleeding), the total score, risk category, and the parallel ischemic assessment. Record the planned DAPT duration, P2Y12 agent, and whether SAPT will follow. This supports continuity at follow-up, pharmacy reconciliation, and audit of adherence to shared decision-making.

Using this CalcMD calculator

Enter age, hemoglobin (g/L or g/dL), white blood cell count (×10⁹/L), creatinine clearance (mL/min), and whether prior spontaneous bleeding requiring medical attention is present. The tool applies the published nomogram axes, displays a per-variable point breakdown, computes the total PRECISE-DAPT score (0–100), and assigns non-high (≤ 17), moderate (18–24), or high (≥ 25) bleeding risk with DAPT duration-oriented messaging aligned to lib/precise-dapt-score.ts.

Use the output for education, structured documentation, and shared decision-making alongside ischemic risk scores and current cardiology guidelines. It does not replace clinical judgment.